Widely used:Recently Viewed
Clear All
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$123 Mln
P/E Ratio
--
P/B Ratio
20.13
Industry P/E
--
Debt to Equity
-1.8
ROE
-11.17 %
ROCE
-28.43 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-49.95 Mln
EBITDA
$-64.11 Mln
Net Profit
$-164.66 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Theratechnologies (THTX)
| 44.20 | 65.71 | 50.87 | 103.91 | -37.40 | -20.46 | -3.68 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Theratechnologies (THTX)
| -54.12 | -70.96 | 21.20 | -24.24 | -45.90 | 6.37 | 175.59 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 3.05 | 605.08 | -- | -68.76 | |
| 4.69 | 1,670.20 | -- | 4 | |
| 1.74 | 657.95 | 15.64 | 3.8 | |
| 6.22 | 6.17 | -- | -114.92 | |
| 6.22 | 6.17 | -- | -114.92 |
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess... abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its product pipeline includes tesamorelin F8 in HIV-associated lipodystrophy that is in Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; SORT1+ Technology that is in Phase 1 clinical trials for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; sudocetaxel zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company also commercializes olezarsen, an RNA-targeted medicine for the treatment of familial chylomicronemia syndrome and severe hypertriglyceridemia; and donidalorsen, an RNA-targeted medicine that targets the acute attacks of hereditary angioedema. The company was incorporated in 1993 and is headquartered in Montreal, Canada. Address: 2015 Peel Street, Montreal, QC, Canada, H3A 1T8 Read more
President, CEO & Director
Mr. Paul Lévesque
President, CEO & Director
Mr. Paul Lévesque
Headquarters
Montreal, QC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Theratechnologies Inc (THTX) stood at $ 53 Mln as on 30-Nov-24
The share price of Theratechnologies Inc (THTX) is $2.61 (NASDAQ) as of 17-Apr-2025 12:42 EDT. Theratechnologies Inc (THTX) has given a return of -37.4% in the last 3 years.
Theratechnologies Inc (THTX) has a market capitalisation of $ 123 Mln as on 16-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Theratechnologies Inc (THTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Theratechnologies Inc (THTX) and enter the required number of quantities and click on buy to purchase the shares of Theratechnologies Inc (THTX).
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its product pipeline includes tesamorelin F8 in HIV-associated lipodystrophy that is in Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; SORT1+ Technology that is in Phase 1 clinical trials for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; sudocetaxel zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company also commercializes olezarsen, an RNA-targeted medicine for the treatment of familial chylomicronemia syndrome and severe hypertriglyceridemia; and donidalorsen, an RNA-targeted medicine that targets the acute attacks of hereditary angioedema. The company was incorporated in 1993 and is headquartered in Montreal, Canada. Address: 2015 Peel Street, Montreal, QC, Canada, H3A 1T8
The CEO & director of Mr. Paul Lévesque. is Theratechnologies Inc (THTX), and CFO & Sr. VP is Mr. Paul Lévesque.
There is no promoter pledging in Theratechnologies Inc (THTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
279
|
|
|
75
|
|
|
69
|
|
|
1
|
| Theratechnologies Inc. (THTX) | Ratios |
|---|---|
|
Return on equity(%)
|
36
|
|
Operating margin(%)
|
4.8
|
|
Net Margin(%)
|
-9.67
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Theratechnologies Inc (THTX) was $0 Mln.
$0.04
(
